Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters - patient centered endpoints in trials of maintenance therapy

Giovanni Scambia, Michael Friedlander, J. Rau, C. K. Lee, W. Meier, A. Lesoin, J. W. Kim, A. Poveda, M. Buck, M. Shimada, F. Hilpert, M. T. King, P. Debruyne, A. Bologna, S. Malander, B. J. Monk, E. Petru, P. Calvert, T. J. Herzog, C. BarrettA. Du Bois

Risultato della ricerca: Contributo in rivistaArticolo in rivista

14 Citazioni (Scopus)

Fingerprint

Entra nei temi di ricerca di 'Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters - patient centered endpoints in trials of maintenance therapy'. Insieme formano una fingerprint unica.

Medicine & Life Sciences